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The United States (US) aviation in-
dustry provides a potentially useful 
mental model for dealing with certain 
cost-benefit decisions in aesthesiology. 
The Federal Aviation Administration 
(FAA), the national aviation authority of 
the United States, quantifies a price 
for the value of a human life based on 
the U.S. Department of Transporta-
tion’s (DOT) value of a statistical life 
(VSL) unit. The current VSL is around 
$9.6 million, indexed to grow with con-
sideration given to inflation and wage 
changes from the 2016 baseline of 
$9.4 million [1]. To illustrate the con-
cept, if the FAA estimates that 100 peo-
ple are likely to die in the future given 
the current practice standards then 
the monetary cost of this loss will be 
$940 million. The FAA uses this esti-
mated monetary value as an official ref-
erence point in its regulatory decisions, 
and the agency publishes in detail how 
it derives the estimated value. When 
proposing new regulations, the FAA 
bases its decisions on comparisons of 
the human life cost associated with the 
existing regulation versus the alterna-
tive cost that the industry stakeholders 
will incur subsequent to the adoption 
of the regulation. In this example, if the 
cost incurred by the industry is more 
than the $940 million cost then the FAA 
will not adopt the proposed regulation 
and hence will not require the industry 
to undertake this cost. 
The complexity of these extensive 
FAA benefit-cost analyses is impres-
sive, but what is also interesting is the 
level of involvement of the industry in 
this process. The FAA publishes their 
calculations of their estimates and in-
vites industry stakeholders to respond 
with alternative estimations and rea-
soning. The FAA addresses the merit 
of alternative estimations in a public 
discussion that resembles the peer 
review process of an academic journal. 
The FAA has applied this process 
to duty hour regulations, prevention 
and testing of alcohol and drug mis-
use, and the frequency and extent of 
recurrent training and testing. These 
topics are pertinent to anaesthesiol-
ogy. To illustrate, in its ruling the FAA 
notes that “The recurrent training/
testing required annually for each 
pilot will start in the second year of 
the 10-year time frame of the rule. 
The FAA estimates that the training will 
take approximately 15 minutes and 
cost $12 ($48 per hour × .25) per pilot. 
This cost estimate multiplied by the 
total number of pilots (29,300) results 
in estimated annual recurrent train-
ing costs of $350,000. Over the next 
10 years, this cost will be $3.2 mil-
lion (or $2.2 million, discounted)… 
The final rule will generate potential 
safety benefits of $14.2 million (or 
$10.0 million, discounted) over the 
next 10 years” [2]. 
In aesthesiology we are constantly 
faced with having to decide whether 
to adopt new technologies or drugs. 
As another example, in recent years 
sugammadex has gained popularity 
and attention as an alternative agent 
for reversal of neuromuscular block-
ade. Some clinicians use it routinely for 
block reversal instead of neostigmine 
while others opt to use it more selec-
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tively. In our opinion, it is reasonable 
for professional societies in the field or 
other regulatory agencies to consider 
issuing guidance documents based 
on estimated rates of expected or ob-
served adverse events. For example, if 
it is believed that one patient a year will 
die from hypoventilation-related com-
plications in an average post-anaesthe-
sia care unit, then this would represent 
a cost of $9.4 million per practice. On 
the other hand, if on average a practice 
performs 150,000 surgeries with paral-
ysis a year and incurs an average cost of 
$100 per sugammadex administration, 
then the relative cost of such standard 
would be $15 million per practice, and 
therefore adoption of such guidelines 
would not be favoured. The above is 
a mere example, not an actual analysis 
of the cost-benefit of sugammadex. 
If one was to undertake a thorough 
cost-benefit analysis of sugammadex, 
other aspects such emergence time 
and OR facility cost and throughput 
time costs would have to be considered 
as well. Other areas of practice in which 
the VSL approach may serve useful are 
the need for pre-operative “clearance” 
visits and pre-operative testing such 
as EKG, Echo, carotid ultrasound, and 
blood testing. This cost approach may 
be useful in assessing protocols that 
call for the use of certain specialized 
equipment for the purpose of prevent-
ing rare occurrences such as airway or 
operating room fires.
Despite the many parallels that 
can be drawn between anaesthesia 
and aviation, some considerable dif-
ferences remain in the risk assessment 
approach to possible negative out-
comes in these different industries. 
The negative outcome in aviation can 
be viewed as mainly binary (death vs. 
no death) whereas medical adverse 
events are not simply a mortality un-
certainty but obviously are further 
complicated by morbidity outcomes. 
The DOT further provides values for 
different disutility levels through their 
Abbreviated Injury Scale (AIS) which 
categorizes injuries into six severity 
levels and assigns them the following 
VSL fraction: minor (0.03), moderate 
(0.047), serious (0.105), severe (0.266), 
critical (0.593), and unsurvivable (1.0). 
These relative values as well as the 
VSL are likely to differ among different 
countries, so the cost-benefit conclu-
sions may differ as well.
The doctor-patient relationship is 
a fiduciary obligation that, like many 
human decisions, is financially influ-
enced. It is important to consider that 
cost-benefit analyses often vary enor-
mously from the perspective of an in-
dividual player vs. the collective group 
perspective. As a  result, there are 
times when a conflict exists between 
the individual player’s incentives 
and the incentives of society. These 
situations, in our opinion, are where 
the FAA’s VSL approach provides the 
most merit because it emphasizes 
collective value, which arguably is 
the regulator’s role. Accordingly, we 
propose the VSL approach as a tool 
for professional societies or medical 
boards, not for decision-making in 
an individual anaesthesia practice.
We wish to stress that assigning 
this proposed monetary value to a hu-
man life in no way devalues it. On the 
contrary, in the US the VSL is much 
higher than the average malpractice 
claim indemnity of $309,066 based 
on the incidence of anaesthesia closed 
malpractice claims [3]. The FAA ap-
proach is a very pragmatic and practi-
cal one and, in our opinion, applicable 
to certain regulatory decisions in an-
aesthesia.
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